Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies exert similar pro-thrombotic effects in peripheral blood monocytes and endothelial cells.
Anti-phosphatidylserine/prothrombin
Anti-phospholipid syndrome
Anti-β2-glycoprotein I
Nitric oxide
Tissue factor
Journal
Auto- immunity highlights
ISSN: 2038-0305
Titre abrégé: Auto Immun Highlights
Pays: England
ID NLM: 101532391
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
05
10
2018
accepted:
25
03
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
The introduction of the anti-phosphatidylserine/prothrombin (aPS/PT) antibodies among the routinely investigated anti-phospholipid (aPL) antibodies led to an improvement in anti-phospholipid syndrome (APS) laboratory diagnostic performance; however, their pathogenic mechanism is still substantially undefined. To support clinical data and future inclusion as possible new criteria antibodies, we designed a head-to-head study to directly compare the procoagulant effects sustained in vitro by aPS/PT to those sustained by anti-β2-glycoprotein I (aβ2GpI) domain 1-specific antibodies. Blood donors-derived monocytes and endothelial cells (HUVEC) were stimulated with lipopolysaccharides (LPS) alone or in combination with the IgG fractions isolated from the serum of six APS patients, positive only for aβ2GpI or for aPS/PT antibodies. As control, cells were incubated with LPS plus the IgG isolated from blood donors. Tissue factor (TF) mRNA expression was measured after four hours incubation by real-time PCR. Nitric oxide (NO) levels were measured in cells supernatant after 16 h incubation by colorimetric assay. aPS/PT and aβ2GpI IgG antibodies fractions showed comparable ability to enhance LPS-induced TF mRNA expression, either in monocytes and in HUVEC. Compared to LPS alone, we found that NO levels are strongly overproduced in HUVEC treated with LPS plus aβ2GpI and aPS/PT IgG fractions. Our data support the significant and independent role of aPS/PT in the pathogenesis of the thrombotic events in APS patients, possibly adding new light to the therapeutic management of cases characterized by the sole presence of aPS/PT IgG antibodies.
Identifiants
pubmed: 32257059
doi: 10.1186/s13317-019-0113-9
pii: 113
pmc: PMC6909027
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Lupus. 2003;12(7):539-45
pubmed: 12892395
J Thromb Haemost. 2003 Mar;1(3):523-31
pubmed: 12871461
Rheumatology (Oxford). 2013 Oct;52(10):1775-84
pubmed: 23878313
Clin Chem Lab Med. 2015 Jul;53(8):1265-70
pubmed: 25562605
Lupus. 2013 Nov;22(13):1349-52
pubmed: 23989738
J Intern Med. 2011 Aug;270(2):110-22
pubmed: 21323768
Clin Chem Lab Med. 2017 May 1;55(6):890-898
pubmed: 27816952
Rheumatology (Oxford). 2018 Apr 1;57(4):661-665
pubmed: 29342292
Arthritis Care Res (Hoboken). 2018 Apr;70(4):627-634
pubmed: 28686816
Inflammation. 2014 Oct;37(5):1439-43
pubmed: 24604342
Clin Chem Lab Med. 2018 Mar 28;56(4):614-624
pubmed: 29166262
Lupus. 2017 Mar;26(3):266-276
pubmed: 27510605
Auto Immun Highlights. 2014 Aug 14;5(2):63-7
pubmed: 26000157
J Autoimmun. 2014 Dec;55:42-50
pubmed: 24685231
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Blood Coagul Fibrinolysis. 2016 Mar;27(2):176-84
pubmed: 26366826
Immunol Res. 2013 Jul;56(2-3):432-8
pubmed: 23572433
Thromb Res. 2013 Oct;132(4):408-13
pubmed: 24054056
Thromb Haemost. 2013 Apr;109(4):643-51
pubmed: 23467542
Lupus. 2011 Feb;20(2):191-205
pubmed: 21303836
J Immunol. 2017 Apr 1;198(7):2640-2648
pubmed: 28193831
Blood. 2004 Oct 15;104(8):2353-8
pubmed: 15226179
Curr Rheumatol Rep. 2015 Mar;17(3):16
pubmed: 25761923